Abstract. Histone deacetylase 6 (HDAC6) is currently being discussed as a promising therapeutic target for the treatment of Alzheimer's disease (AD). Mounting evidence indicates that increased HDAC6 expression may contribute to AD-associated neurodegeneration, although beneficial effects have also been identified. In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD. We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-␤ (A␤) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects. Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced production and facilitated autophagic clearance of A␤ and hyperphosphorylated tau. Further, the decreased hyperphosphorylated tau and increased tubulin acetylation may account for the improved microtubule stability in AD mice after tubastatin A/ACY-1215 treatment. These preclinical results support the detrimental role of HDAC6 in AD, and offer prospective approaches for using tubastatin A/ACY-1215 as potential therapeutic strategy for AD.
INTRODUCTION
Alzheimer's disease (AD), a devastating neurodegenerative disorder associated with progressive cognitive decline, is characterized by extracellular deposit of amyloid-␤ (A␤) peptides in senile plaques and accumulation of hyperphosphorylated tau (Ptau) proteins in neurofibrillary tangles. Despite much progress, the underlying pathogenesis of AD remains to be elucidated and effective treatments are not currently available. Over the past decade, lots of studies in vitro and vivo have identified many compounds of therapeutic interest [1, 2] . Among these compounds, histone deacetylase (HDAC) inhibitors such as trichostatin A and suberoylanilide hydroxamic acid (SAHA) have shown neuroprotective effects [3] [4] [5] . However, these inhibitors are not specific for a certain HDAC. They target not only class I HDACs, but also class II, such as HDAC6. Unlike other HDACs, HDAC6 is a unique cytoplasmic HDAC that deacetylates many non-histone proteins (e.g., ␣-tubulin, HSP90, cortactin) with two catalytical domains and a ubiquitin interacting domain [6, 7] .
HDAC6 levels in brain regions related to learning and memory, such as hippocampus and cortex increase significantly in AD patients and models. Mounting evidence supported that HDAC6 overexpression may contribute to the neurodegeneration in AD, although beneficial effects have also been identified [8] [9] [10] . A recent study demonstrated that reducing endogenous HDAC6 restores learning and memory abilities in a mouse model for AD [11] . Based on previous data, we reviewed the possible roles of HDAC6 in AD [7] and here we investigated the potential effects of tubastatin A and ACY-1215, two selective HDAC6 inhibitors, on behavioral deficits in AD transgenic mice [12, 13] . We found that both tubastatin A and ACY-1215 improved cognitive function in A␤PP swe /PS1 E9 (PAP) mice. The possible mechanisms included increased microtubule stability, enhanced autophagy and reduced amyloid and tau pathology. Our results suggest that tubastatin A and ACY-1215 may be potential drugs to treat AD.
MATERIALS AND METHODS

Animals
The A␤PP swe /PS1 E9 (PAP) double-transgenic mice (C57BL/6J) were generated as previously described [14] . The use of animals was in compliance with the Health Guide for care and use of Laboratory Animals. The study protocol was approved by the Animal Care and Use Committee of the Institute of Laboratory Animal Science of Peking Union Medical College (ILAS-PL-2012-003).
Groups and treatments
Six-month-old male and female mice were divided into six groups: the wild-type control (WT, n = 16), model control (PAP), vehicle (DMSO/saline = 1:10), SAHA, tubastatin A, and ACY-1215 groups. For SAHA (Selleck, S1047), tubastatin A (Selleck, S8049), and ACY-1215 (MedKoo, 205808) treatments, we dissolved the compounds in DMSO (SigmaAldrich) and further diluted them in saline to the final doses. We treated transgenic mice for 20 consecutive days by daily intraperitoneal injection of 50 mg/kg SAHA, 25 mg/kg tubastatin A, 25 mg/kg ACY-1215, or an equivalent amount of vehicle. The doses of the compounds were selected based on other experimental studies [4, 13, 15] .
Behavioral analysis
Behavioral tests were performed as described previously with certain modifications [11, 14, 16] . The anxiety of the mice was analyzed by the open field test. This test utilized Noldus Ethovision XT monitoring and analysis software (Noldus Ltd, Holland). Each mouse had 5 min of free movement in the open field (50 × 50 cm), which was divided into the peripheral zone and the central zone. The time that each mouse stayed in each zone, as well as the frequency with which each mouse was immobile, mobile, or highly mobile, were recorded. Highly mobile and immobile states were defined as mobility rates >60% and <20%, respectively. Mice with an intermediate mobility rate were between the two levels (>20%-<60%).
The reference memory of the mice was assessed using the novel object recognition (NOR) task and the Morris water maze (MWM) test.
The NOR task consists of a habituation phase, a training phase, and a test phase. Mice were firstly habituated to the test box measuring 45 cm × 30 cm × 20 cm for 5 min daily on 2 consecutive days without any object. After habituation phase, two identical objects were introduced. And mice were allowed to explore freely for 5 min daily on 3 consecutive days. In the test phase, each mouse was placed in the arena with a familiar object they explored during the training phase and a novel object of different shape and color. The exploration time for the familiar (T F ) or the novel object (T N ) during the test phase was videotaped and analyzed using the Noldus Ethovision XT software (Noldus Ltd, Holland). The discrimination index (DI = (T N -T F ) / (T N +T F ) × 100%) was used to measure memory preference.
The MWM test was performed in a circular tank (100 cm in diameter) filled with water (22 ± 1 • C) that was made turbid with powdered milk. An escape platform (10 cm in diameter) was submerged 0.5 cm below the water surface in the center of one of the four quadrants of the maze. Each mouse was subjected to two trials each 1 min long for five consecutive days. The time taken to reach the platform (escape latency) was recorded and the average of two trials was determined. In the probe trial, mice swam freely in the tank without platform for 1 min, and the time and frequency spent in the quadrant of the original platform and other quadrants was recorded. Each mouse was kept dry in a plastic holding cage on an electric heater after the swim. The room temperature was constant and the light levels were even. Monitoring was performed with the Noldus Ethovision XT system.
Histochemical staining
Brain tissue from the mouse (n = 5) was fixed in 10% neutral buffered formalin and embedded in paraffin. After dewaxing, the cortical sections (8 m thickness) were washed in PBS. For thioflavin-S staining, sections were incubated in 0.25% potassium perman-ganate and 1% oxalic acid until they appeared white. Then the sections immersed in water and stained for 5 min with 1% thioflavin-S solution in 50% ethanol. Finally, the sections were washed and dehydrated followed by mounting with coverslips and analyzed by using ImageJ software (1.43u, NIH, USA).
The immunohistochemistry procedures were carried out as the conventional methods. Sections were probed with primary antibody: ace-␣-tubulin (1:1000, Sigma)/6E10 (1:1000, Convance) overnight at 4 • C. Then, the immunoreaction was visualized after incubating with the secondary antibody (HRP-labeled anti-rabbit/mouse IgG) and DAB (ZSGB-BIO, Beijing, China). Positive sections were scanned with Aperio Scanscope XT (Aperio Technologies, Vista, CA) and analyzed using Image Pro-Plus 6.0 software (Media Cybernetics Inc., USA). and Aβ Soluble and insoluble A␤ and A␤ was extracted according to previous studies [14, 17] . In brief, the frozen mouse brain was weighed and homogenized with ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) to the frozen tissue at 4:1 (TBS volume/brain wet weight). The homogenate was centrifuged at 4 • C for 30 min at 20,000 g. The supernatant containing soluble A␤ peptide was aliquoted and then stored at −80 • C. The precipitate containing insoluble A␤ was re-homogenized in an equal volume of TBS plus 5 M guanidine HCl (pH8.0) and incubated for 4 h at room temperature. The supernatant was regarded as the insoluble A␤ fraction. A␤ and A␤ 1-42 levels were quantified by ELISA according to the manufacturer's protocol (Invitrogen, KHB3482/3442).
ELISA test for Aβ
Immunoblotting
Brain tissue was homogenized in RIPA buffer containing 0.1% PMSF and 0.1% protease inhibitor cocktail (Pierce, 78428). The lysates were centrifuged at 14,000 rpm for 30 min at 4 • C. The protein concentration in supernatant was measured by BCA assay kit (Pierce, Rockford, IL, USA, 23225). The procedures were performed as the conventional methods [11] . Quantitative analysis was performed by densitometry using NIH ImageJ software. Immunoblotting was carried out with antibodies specific for ace-␣-tubulin (K40), ␣-tubulin (1:1000, Sigma); HDAC6, SIRT1 (1:500, Millipore); A␤PP, sA␤PP␣ (6E10), A␤PP C-terminal (1:1000, Convance); sA␤PP␤, BACE1, ADAM10, PS1, LAMP2, Beclin1, HDAC1/2, H3K9/H3, H4K8/H4 (1:500, Abcam); AT8, AT100, AT180, AT270, PHF1 (1:300, Pierce), Tau5 (1:500, Calbiochem); LC3I/3II, P-mTOR (Ser2448), mTOR, CDK5, p-GSK3␤ (Ser9), GSK3␤, P-Akt (Ser473), Akt (1:1000, Cell Signaling). Variations in sample loading were corrected by normalizing to GAPDH levels.
Electron microscopy
Ultrastructural analysis was performed as previous studies [16] . Briefly, brains were removed after cardiac perfusions with 0.01 M PBS (pH 7.4) containing 2% paraformaldehyde. The frontal cortex and hippocampal CA1 were carefully dissected and fixed in 2.5% glutaraldehyde solution at 4 • C for 2 h. The samples were treated with 1% osmium tetroxide in 0.1 M cacodylate buffer for an additional 1 h, followed by 1% uranyl acetate and dehydrated in ethanol. Samples were embedded in epoxy resin, sectioned (90 nm) and placed on carbon-coated copper grids. After uranyl acetate and lead citrate staining, the specimens were observed with transmission electron microscopy (JEOL JEM-1400).
Assessment of toxicity of HDAC6 inhibitors
Blood was obtained from four mice in each group via cardiopuncture at the time of sacrifice. Then serum was collected and immediately subjected to biochemical examination (Supplementary Table 2 ). Tissues of liver, kidney, and brain were collected after sacrifice. 5 m thick sections were cut and stained with hematoxylineosin (H&E) for histopathological evaluation.
Statistical analysis
All data were shown as means ± SEM. The escape latencies in the MWM test were analyzed using two-way ANOVA with repeated measures. Other differences between groups were examined by one way ANOVA followed by Dunnett's post hoc multiple comparison tests using SPSS 19.0. In all tests, p < 0.05 was considered as statistically significant.
RESULTS
Tubastatin A and ACY-1215 ameliorate cognitive deficits in AβPP swe /PS1 ∆ E9 mice without significant effects on anxiety levels
The open field test was used to examine anxiety levels in the mice. The A␤PP swe /PS1 E9 (PAP) and vehicle-treated groups showed an increased frequency of immobile, mobile and highly mobile states compared with WT littermates (p < 0.01 respectively) (Fig. 1a) . These two groups spent more time in the peripheral zone and less time in the central zone (Fig. 1b) , which indicated that the PAP mice were more hyperactive and anxious. Anxiety levels of the PAP mice were not significantly altered by the inhibitors (Fig. 1a, b) .
To examine whether HDAC6 inhibitors affect cognitive function in PAP mice, we tested spatial learning and memory by MWM. During the whole test, the vehicle-treated group showed similar performance to the PAP group. In the hidden platform test (Fig. 1c,  d ), the vehicle-treated mice showed significantly increased escape latency from day 2 compared to the WT littermates (p < 0.05 for day 2; p < 0.01 for day [3] [4] [5] . SAHA and ACY-1215 groups showed dramatically decreased escape latencies from day 3 (p < 0.01 for day 3-5, respectively), and tubastatin A group at day 5 (p < 0.01) compared with the vehicle group. Interestingly, mice of ACY-1215 group showed shorter escape latency than those of SAHA (p < 0.01 for day 4, p < 0.05 for day 5), and tubastatin A groups (p < 0.01 for day 4-5 respectively). These results revealed that the impaired acquisition of the spatial learning task in PAP mice was rescued by tubastatin A and ACY-1215. ACY-1215-treated mice exhibited a better spatial learning performance than SAHA and tubastatin A.
In the subsequent probe test, preference for the target quadrant was significantly impaired in the PAP and vehicle controls compared with the WT littermates (Fig. 1e) . However, this impairment can be corrected by tubastatin A or ACY-1215 treatment (Fig. 1e ). This implied that tubastatin A and ACY-1215 reversed the spatial memory deficit in AD mice.
In addition, we tested recognition memory by the NOR task. A one-way ANOVA analysis revealed that the discrimination index (DI), reduced in the model controls (PAP) and vehicle-treated mice, was significantly improved in HDACi-treated groups (Fig. 1f) . As shown in Fig. 1f , DI was increased by nearly 88%, 75%, and 70% in SAHA, tubastatin A, and ACY-1215 groups, respectively, compared with the vehicle-treated group. Collectively, these data suggest that tubastatin A/ACY-1215 as well as SAHA can restore cognition in AD mice.
Tubastatin A and ACY-1215 increase α-tubulin acetylation with relative specificity for HDAC6
After sacrificing the mice, we first tested the specificity of tubastatin A and ACY-1215. In line with previous studies, we observed a dramatic increase in the level of HDAC6 in the PAP and vehicle-treated mice compared with the WT littermates (Fig. 2b) . But neither tubastatin A nor ACY-1215 has a significant influence on the expression of HDAC6 compared (1, 4) , was absent in HDAC6i-treated groups (2, 3, 5, 6) . The number of AVs was reduced (7-10) and axon degeneration (2, 3) was improved in HDACi-treated groups (n = 3). Scale bar: 5 m (1, 2, 3); 1 m (4-9); 500 nm (10) .
with the PAP and vehicle-treated mice (Fig. 2b) . Since ␣-tubulin is one of the most important substrates of HDAC6, we examined the level of acetylated ␣-tubulin (K40), which is a marker of HDAC6 activity [15, 18] . As expected, we found an apparent reduction in the level of acetylated ␣-tubulin in the hippocampus and prefrontal cortex of the PAP and vehicle-treated mice compared with the WT littermates, which was reversed by tubastatin A and ACY-1215 (Fig. 2a,  b) . Thus, both tubastatin A and ACY-1215 inhibited the activity of HDAC6 rather than its expression level.
Besides, SAHA treatment resulted in a marked elevation of histone acetylation through inhibiting class I HDACs (Fig. 2c) , while neither tubastatin A nor ACY-1215 brought such result (Fig. 2c) [4] .
Tubastatin A and ACY-1215 reduce Aβ deposition in AβPP swe /PS1 ∆E9 mice
To determine the mechanisms underlying the effects of tubastatin A and ACY-1215 on cognitive function, we analyzed A␤ plaque load using thioflavin-S and 6E10 staining (Fig. 3a) . As shown in Fig. 3a , the WT littermates presented no visible plaque. However, plenty of plaques accumulated in the hippocampus and cortex of the PAP and vehicle-treated mice, whereas mice treated with the HDAC6 inhibitors displayed reduced plaque deposition compared with the PAP and vehicletreated controls (Fig. 3a, b) . Furthermore, we measured the levels of soluble and insoluble A␤ and A␤ in mice brains by ELISA. Our results revealed a dramatic decrease in levels of soluble A␤ and A␤ 1-42 in HDAC6i-treated groups compared with the vehicle controls (Fig. 4a) .
Tubastatin A and ACY-1215 reduce Aβ deposition by inhibiting β/γ-secretase cleavage of AβPP and promoting autophagy
We next examined the effects of tubastatin A and ACY-1215 on A␤ production and elimination, including degradation process of A␤PP (Fig. 4b) and levels of several autophagy-related proteins (Fig. 4c) by western blot analysis. Come to light, A␤ 1-40/1-42 was derived from sequential cleavages of A␤PP by ␤-and ␥-secretase and produced neurotoxic effect, while its cleavage by ␣-secretase (ADAM10) precludes neurotoxic A␤ peptide production and generates neurotrophic sA␤PP␣ and ␣-CTF (C83) [19] . Immunoblot analysis manifested that the levels of sA␤PP␤, BACE1 (␤-secretase), ␤-CTF (C99), and PS1 (the catalytic core of ␥-secretase) significantly decreased, whereas there were no changes in ␣-cleavage-related proteins in HDAC6i-treated mice compared with the vehicle controls (Fig. 4b) .
Moreover, we tested the levels of several autophagyrelated proteins, including LC3II/I, Beclin1, and LAMP2 (lysosomal-associated membrane protein 2) [20] [21] [22] [23] . We found that treatment with tubastatin A or ACY-1215 facilitated autophagy (referred as macroautophagy) by upregulating autophagy-related proteins and inhibiting the phosphorylation of mTOR, which is a negative regulator of autophagy (Fig. 4c) [24] [25] [26] .
Interestingly, using transmission electron microscopy, we observed atypical amyloid plaque structures in all HDAC6i-treated groups (including SAHA, tubastatin A, and ACY-1215 groups). As shown in Fig. 3c , the plaque core seemed to be dissolved, and the dystrophic neuritis surrounded the plaque showed a sign of revival in brains of SAHA/ACY-1215-treated mice. Meanwhile, the numbers of autophagic vesicles (AVs) declined significantly in all HDAC6i-treated mice compared with the vehicle-treated controls (Fig. 3c, Supplementary  Table 1 ). All these data suggested that tubastatin A and ACY-1215 may reduce A␤ deposition not only by inhibiting ␤/␥-secretase cleavage of A␤PP but also by promoting autophagy.
Tubastatin A and ACY-1215 attenuate tau hyperphosphorylation via inhibiting Akt/GSK3β signaling pathway and consequently restore microtubule stability
Since HDAC6 was demonstrated to be a tauinteracting protein and a modulator of tau phosphorylation and accumulation, we tested the level of tau hyperphosphorylation by western blot analysis [7] [8] [9] [27] [28] [29] . Our results represented that tubastatin A or ACY-1215 treatment reduced tau hyperphosphorylation (Fig. 5a) . Moreover, we examined the levels of protein kinases that phosphorylate tau, such as CDK5 and GSK3␤ [30] . We found that the level of CDK5 decreased in both tubastatin A and ACY-1215 groups compared with the vehicle group. Meanwhile, all the HDAC6 inhibitors significantly increased the phosphorylation of GSK3␤ at the Ser9 site, an inhibitory site of GSK3␤ activity. That is, GSK3␤ activity was inhibited by the HDAC6 inhibitors.
As an HDAC6-interating protein, GSK3␤ is also a downstream target of Akt involved in several signal transduction pathways [31] . And then, we evaluated the effect of tubastatin A and ACY-1215 on the phosphorylation of Akt (Ser473). The result showed that phosphorylation of Akt increased in tubastatin A and ACY-1215 groups as expected (Fig. 5b) . Moreover, the ultrastructual analysis displayed that the damage of microtubule in AD transgenic mice was rescued by tubastatin A or ACY-1215 treatment (Fig. 5c) . According to the results above, the improvement of microtubule stability may achieve through increasing tubulin acetylation and decreasing tau hyperphosphorylation via inhibiting Akt/GSK3␤ pathway by HDAC6 inhibition.
HDAC6 inhibitors show no significant adverse effects on mice
After administration of the HDAC6 inhibitors, a battery of experiments designed to detect possible side effects on animals. However, there was no detectable change in gross brain morphology and brain/body mass (Supplementary Figure 1a) . Further, liver enzyme measurements and kidney function tests were performed (Supplementary Table 2 ). The results revealed no significant effects on liver and kidney function in mice treated with tubastatin A or ACY-1215, while there were dramatic increases in levels of lactic dehydrogenase and urea nitrogen in SAHA-treated mice (Supplementary Table 2 ). Microscopic examinations of different tissues, including brain, liver, and kidney, showed no obvious severe abnormity in all groups except SAHA-treated group (Supplementary Figure 1b) . As Fig. 6b shows, the hepatocytes exhibited hyaline degeneration and inflammatory reaction in SAHA-treated mice.
DISCUSSION
Since HDAC6 overexpression was demonstrated to play an important role in the pathogenesis of AD, it is meaningful to study the potential of selective HDAC6 inhibitors to treat AD [7] [8] [9] [10] [11] .
Currently, many HDAC6 inhibitors have been identified. Most of the known inhibitors are pan-HDAC inhibitors. For instance, SAHA, approved for the treatment of cutaneous T-cell lymphoma, was previously demonstrated to reverse contextual memory deficient in A␤PP swe /PS1 E9 mice [3, 4] . Thus, we used it as the positive control. To date, a limited number of selective HDAC6 inhibitors have been identified [3, 32] . Among these selective inhibitors, tubacin was first identified and widely used in vitro. However, as a consequence of its non-drug-like properties, high lipophilicity, and tedious synthesis, it is more useful as a research tool than as a drug [32] [33] [34] . In the present study, we choose two selective inhibitors to treat AD mice. One is tubastatin A, demonstrated to show neuroprotection in vitro and vivo with high selectivity, activity, and drug-like structure [12, 15, 35] . The other is ACY-1215, a novel compound under phase II clinical trial for multiple myeloma. ACY-1215 is considered to be a promising potential drug due to many properties, including high selectivity, suitable oral bioavailability, cellular permeability, metabolic stability, and minimal drug-drug interaction [13, 32] .
In this study, we examined the effects of the two selective inhibitors on the non-spatial working memory by NOR task, hippocampus-dependent spatial learning and memory by MWM test, and some related neuropathies by molecular and morphological tests [11, 14] . Our data indicated that the cognitive impairment and neuropathies of AD could be halted and even reversed by tubastatin A and ACY-1215, at least in animal models. Such reversibility was also found in SAHA-treated group. But interestingly, tubastatin A and ACY-1215 show less hepatotoxicity compared to SAHA, which may be attributed to their high selectivity and limited effects on histone acetylation. In addition, there is no essential difference between tubastatin A and ACY-1215.
Our molecular and morphological results denote that preservation of learning and memory function by inhibiting HDAC6 is likely to involve multiple cellular processes. SAHA was previously confirmed to compensate for transport deficit by increasing tubulin acetylation [6, 18] , so we detected the acetylation of ␣-tubulin. Expectedly, the level of acetylated ␣-tubulin notably increases in both tubastatin A and ACY-1215 groups. This can lead to enhanced microtubule stability and axonal transport of BDNF/mitochondria through recruitment of kinesin-1 and dynein to the more acetylated microtubule [18, [36] [37] [38] [39] [40] . On the other hand, acetylated microtubule is also required for fusion of autophagosomes with lysosomes. Increased acetylated ␣-tubulin in tubastatin A and ACY-1215 groups may enhance the fusion of autophagosomes with lysosomes and then promote the autophagy process (Figs. 4c, 5c , and 6e) [41] .
Moreover, HDAC6, as a microtubule-associated protein (MAP) also interacts with another MAP-tau, which exists in abnormal hyperphosphorylated form in AD brain. And hyperphosphorylated tau also collapses the transport system of neurons via microtubule disintegration [8, 9, 29] . After treatment with HDAC6 inhibitors, we observed that hyperphosphorylation of tau at Ser202/Thr205, Thr231, and Ser396/Ser404 were apparently attenuated compared with the vehicle-treated mice. Furthermore, genetic or pharmacological inhibition of HDAC6 was recently demonstrated to rescue tau-induced microtubule defects [29] . Collectively, tubastatin A and ACY-1215 may improve microtubule-dependent axonal transport through increasing acetylation of ␣-tubulin and reducing tau hyperphosphorylation (Fig. 6b) .
To further determine why HDAC6 inhibitors reduce tau hyperphosphorylation, we measured the activity of CDK5 and GSK3␤, two kinases that can phosphorylate tau at several sites referred above [30, 31] and several autophagy-associated parameters [23] . The immunoblot analysis represented that the activity of the kinases, including CDK5 and GSK3␤, was inhibited by tubastatin A and ACY-1215. With regard to GSK3␤, it has to be mentioned that its interaction with HDAC6 may improve the activity of HDAC6 and impair the microtubule-based transport of mitochondria in hippocampus neurons (Fig. 6b ) [39] . Thus, the decreased activity of GSK3␤ may further enhance the inhibitory effect of the HDAC6 inhibitors. Besides, GSK3␤, as a direct downstream target of Akt, is implicated in several signaling pathways and then regulates expression of many genes. Gavilán et al. recently reported that Akt/GSK3␤ signaling pathway determined autophagy activation in tumor cell [42] . Indeed, GSK3␤ negatively regulated autophagy, and elevated GSK3␤ phosphorylation at Ser9 simulated autophagy activation and promoted the expression of autophagy-related proteins, such as LC3II and beclin1 [42] [43] [44] [45] . Parr et al. reported that GSK3␤ inhibition promoted lysosomal biogenesis and autophagic degradation of A␤PP [45] . In the present study, we found that treatment with tubastatin A or ACY-1215 inhibited GSK3␤ activation by enhancing phosphprylation at Ser9 with an increase phosphorylation of Akt. Simultaneously, proteins involved in autophagy process, including LC3II, beclin1, and LAMP2 significantly increased in tubastatin A and ACY-1215 groups compared with the vehicle-treated group. Meanwhile, the level of phospho-form mTOR, an inhibitory factor of autophagy decreased in tubastatin A and ACY-1215 groups. All these data strongly imply that impaired autophagy in AD can be rescued by tubastatin A and ACY-1215 (Fig. 6d) .
Actually, increased p-mTOR contributes to ADlinked cognitive deficits involved in many cellular processes, including both the buildup and clearance of toxic protein aggregates such as A␤ and P-tau [46] [47] [48] . A recent study has reported that increasing mTOR activity elevated endogenous tau hyperphosphorylation, while reducing mTOR signaling ameliorated tau pathology and the associated behavioral deficits in a mouse model overexpressing mutant human tau. Furthermore, they provided compelling evidence that the association between mTOR and tau was linked to GSK3␤ and autophagy function [47] . In addition, loss of HDAC6 was demonstrated to alleviate abnormal tau accumulation via promoting tau clearance [28] . Given the overwhelming evidence, we speculate that tubastatin A and ACY-1215 reduce tau pathology through decreasing tau phosphorylation and increasing autophagy-associated degradation via Akt/GSK3␤/mTOR signaling pathway by selective HDAC6 inhibition (Fig. 6d) .
Here, it has to be mentioned that mTOR is also a downstream target of Akt [48] . However, the level of phospho-form Akt increased obviously after Tubastatin A or ACY-1215 treatment compared with the vehicle controls. This suggested mTOR might have a negative feedback effect on Akt. The increased phospho-form Akt elevated the level of GSK3␤ phosphorylation and then induced subsequent effects. All these results imply that tubastatin A and ACY-1215 possibly contribute to the elimination of misfolded proteins or aggregates (A␤/P-tau) in AD, through upregulated Akt/GSK3␤/mTOR-mediated autophagy (Fig. 6d) .
It is worth noting that the massive accumulation of autophagic vesicles in AD was rescued by HDAC6 inhibitors, which seems inconsistent with the enhanced autophagy in tubastatin A and ACY-1215 groups described above. But in fact, reduced autophagic vesicles may be a proof supporting the elevated autophagy in inhibitors-treated groups. During last decade, mounting evidence hinted that autophagic pathology observed in AD most likely arose from impaired clearance of autophagic vesicles rather than strong autophagy induction [23, 49, 50] . Meanwhile, HDAC6 was revealed to play a crucial role in the eventual clearance of aggresomes, especially in the autophagosome maturation [51] . Moreover, HDAC6-associated acetylated microtubules are required for fusion of autophagosomes with lysosomes referred before (Fig. 6e) [41] . In addition, the protein levels of LC3II/LAMP2, as evidence of autophagosomelysosome fusion increased dramatically in tubastatin A and ACY-1215 mice [22, 23] . Based on current evidence, we speculate that appropriate inhibition of excessive HDAC6 by tubastatin A or ACY-1215 may rescue autophagic pathology through the following ways: 1) facilitating delivery of autophagic substrates to lysosomes where the contents are degraded via improved microtubule network; 2) elevating levels of autophagy-related proteins via Akt/GSK3␤/mTOR pathway.
The enhanced autophagy induced by tubastatin A/ACY-1215 further promoted the clearance of toxic proteins, including P-tau described above and A␤/oligomers. Taking into account that A␤ deposition is a crucial event of AD pathogenesis, A␤ deposition was analyzed in all groups. Surprisingly, we observed that HDAC6 inhibitors reduced A␤ plaque and soluble A␤ (including A␤ and A␤ ). Our results indicated that tubastatin A/ACY-1215 could reduce A␤ load via inhibiting A␤ production by altering A␤PP processing at the ␤-and ␥-secretase site as well as increasing autophagic clearance (Fig. 4) . The reduced A␤ production after tubastatin A/ACY-1215 administration also seemed to be related to GSK3␤ inhibition. Qing et al. demonstrated that VPA, a pan-HDAC inhibitor, decreased A␤ production by inhibiting GSK3␤ activity through altering its phosphorylation at Ser9. And GSK3␤ was proved to mediate ␥-secretase cleavage of A␤PP [52] . Interestingly, another study reported that specific inhibition of GSK3␤ markedly reduced BACE1-mediated ␤-cleavage of A␤PP and A␤ deposition, and alleviated memory deficits in AD mice [53] . Altogether, we conclude that tubastatin A/ACY-1215 may reduce A␤ production via inhibiting both ␤-and ␥-cleavage of A␤PP by GSK3␤ inhibition (Fig. 6c) .
Notably, it is very likely that inhibited GSK3␤ activity induced by HDAC6 inhibition may act an essential role in cognitive improvement of AD mice through following ways: 1) reducing A␤ production by inhibiting ␤-/␥-cleavage of A␤PP (Fig. 6c) ; 2) attenuating tau hyperphosphorylation (Fig. 6b); 3) simulating autophagy activation and the expression of autophagy-related proteins (Fig. 6d) [42] [43] [44] [45] ; 4) promoting lysosomal biogenesis and autophagic degradation (Fig. 6e) [45] ; 5) further inhibiting the activity of HDAC6 by weakening its interaction with HDAC6 (Fig. 6b) [39] .
In conclusion, our study indicates that selective inhibition of HDAC6 by tubastatin A/ACY-1215 ameliorates cognitive impairment in an AD mice model. The therapeutic efficacy of selective HDAC6 inhibitors is not limited to axonal transportation due to the improvement of microtubule function. The underlying mechanisms may also include the alleviation of A␤ and tau pathology, two major lesions involved in AD pathogenesis (Fig. 6) . Though tubastatin A and ACY-1215 are not more effective, they are less toxic than SAHA indeed. These preclinical results raise hope for the treatment of AD.
